Fig. 4From: Synergistic co-administration of docetaxel and curcumin to chemoresistant cancer cells using PEGylated and RIPL peptide-conjugated nanostructured lipid carriersCytotoxicity of different formulations on MCF7 and MCF7/ADR cells determined using the MTT assay. A Docetaxel (DTX)-loaded formulations, B curcumin (CUR)-loaded formulations, and C combination of DTX- and CUR-loaded formulations at 1:3 weight ratio. Data represent mean ± SD (n = 3). Significant differences at p < 0.05: * versus drug solution; # versus pNLCBack to article page